Clinical Trial

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Name: Niclosamide in Pediatric Patients With Relapsed and Refractory AML — clinical trial record (NCT05188170)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

Protocol Amendment History 1 change

notable Primary completion pushed: 2026-07 -> 2026-09 2026-08-13

Trial Details

NCT Number	NCT05188170
Lead Sponsor	Stanford University Collaborators: The Leukemia and Lymphoma Society, Pediatric Cancer Research Foundation (PCRF), CURE Childhood Cancer, Inc.
Conditions	Acute Myeloid Leukemia (AML)
Enrollment	16 participants
Start Date	2022-11-21
Primary Completion	2026-09 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-12